SCHEMBL21639720

SCHEMBL21639720

FC(F)(F)c1cccc(CSc2ncnc3[nH]cnc23)c1

nearest known ligand 0.68

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 9/20 0.68
DBF4 Q9UBU7 9/20 0.68
SLC29A1 Q99808 2/20 0.47
DAO P14920 2/20 0.45
RAB9A P51151 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
GFER P55789 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31186596 1.00 CDC7 (0.68) CDC7DBF4SLC29A1DAORAB9A
SCHEMBL31186604 0.85 CDC7 (0.65) CDC7DBF4SLC29A1DAOHPGD
SCHEMBL21639758 0.85 CDC7 (0.65) CDC7DBF4SLC29A1DAOHPGD
SCHEMBL5045055 0.83 CDC7 (0.50) CDC7DBF4HPGDALOX15
SCHEMBL21639769 0.81 CDC7 (0.66) CDC7DBF4SLC29A1HPGDALOX15
SCHEMBL21639771 0.81 CDC7 (0.66) CDC7DBF4SLC29A1HPGDALOX15
SCHEMBL31186616 0.81 CDC7 (0.66) CDC7DBF4SLC29A1HPGDALOX15
SCHEMBL21639756 0.81 CDC7 (0.66) CDC7DBF4SLC29A1HPGDALOX15
SCHEMBL31186618 0.81 CDC7 (0.66) CDC7DBF4SLC29A1HPGDALOX15
SCHEMBL2120063 0.81 CDC7 (0.61) CDC7DBF4RAB9AHPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3604310-B1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CONSEJO SUPERIOR INVESTIGACION (ES) 2024-09-11 EP claimed
US-11446304-B2 CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2022-09-20 US claimed
US-20200093828-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2020-03-26 US claimed
EP-3604310-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-02-05 EP claimed
EP-3604310-B1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CONSEJO SUPERIOR INVESTIGACION (ES) 2024-09-11 EP disclosed
US-11446304-B2 CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2022-09-20 US disclosed
US-20200093828-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2020-03-26 US disclosed
EP-3604310-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093828-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CDC7, TARDBP, CDC14A CDC7 1/4885DBF4 171/4885SLC29A1 1011/4885
US-11446304-B2 CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions CDC7, TARDBP, CDC14A CDC7 1/4885DBF4 171/4885SLC29A1 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.